- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01031186
First Time in Human Study (FTIM)
July 25, 2017 updated by: GlaxoSmithKline
A First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK356278 (PDE4 Inhibitor) in Healthy Volunteers
This study will evaluate the safety, tolerability, and pharmacokinetics of GSK356278 in male volunteers
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
To evaluate the safety, tolerability and pharmacokinetics of single ascending doses of GSK356278 and may assess the effect of food on GSK356278 pharmacokinetics.
They study will assess the compound's effect on nausea, emesis and alertness.
Close monitoring of cardiovascular parameters will be included.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Randwick, New South Wales, Australia, 2031
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- AST, ALT, alkaline phosphate and bilirubin less than or equal to 1.5 times upper limit of normal.
- Healthy as determined by a responsible and experienced physician based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
- Males aged between 18 and 65 years inclusive at the time of signing the informed consent.
- Males must agree to appropriate forms of contraception from administration of first dose through to 3 months after taking the final dose.
- Body weight greater than or equal to 50 kg and BMI within the range of 18-29.9 m2 (inclusive)
- Capable of giving written informed consent.
- QTcB or QTcF less than 450 msec
Exclusion Criteria:
- A positive pre-study Hep B or positive Hep C result within 3 months of screening.
- Current or chronic history of liver disease or known hepatic or biliary abnormalities
- A positive pre-study alcohol and drug screen
- A positive test for HIV antibody.
- History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of greater than 21 units or average daily intake of greater than 3 units
- The subject has participated in a clinical trial and has received investigational product within the time period of 30 days prior to first dosing day (or 5 half-lives or twice the duration of the biological effect of the drug, whichever is longer)
- Exposure to more than 4 new chemical entities in the last 12 months prior to the first dosing day
- Use of prescription or non-prescription drugs including vitamins, herbal and dietary supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose unless in the opinion of the investigator and medical monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of sensitivity to any of the study medication or history of drug or other allergy that in the opinion of the investigator or medical monitor contraindicates their participation.
- Where participation in the study would result in donation of blood or blood products in excess of 500 ml within a 56 day period.
- Unwillingness or inability to follow the procedures in the protocol.
- Subject is mentally or legally incapacitated.
- Subjects who have asthma or a history of asthma.
- Urinary cotinine levels indicative of smoking or history of regular use of tobacco or nicotine containing products within 6 months prior to screening.
- Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose.
- History of any significant psychiatric illness.
- Any history of suicidal behaviour or any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale in the last 6 months.
- History of presence of clinically significant cardiac arrhythmias or other clinically significant cardiac disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1, Session 1
In Dosing Session 1, the subjects will be administered 0.5 mg GSK356278 and placebo in a fasted state.
|
GSK356278
PLACEBO
|
Experimental: Cohort 1, Session 2
In Dosing Session 2, the subjects will be administered GSK356278 (0.5 mg and 1.5 mg) and placebo in a fasted state.
|
GSK356278
PLACEBO
|
Experimental: Cohort 1, Session 3
In Dosing Session 3, the subjects will be administered GSK356278 (1.5 mg and 4 mg) and placebo in a fasted state.
|
GSK356278
PLACEBO
|
Experimental: Cohort 1, Session 4
In Dosing Session 4, the subjects will be administered GSK356278 (4 mg and 8 mg) and placebo in a fasted state.
|
GSK356278
PLACEBO
|
Experimental: Cohort 1, Session 5
In Dosing Session 5, the subjects will be administered GSK356278 8 mg and placebo in a fasted state.
|
GSK356278
PLACEBO
|
Experimental: Cohort 2, Session 1
In Dosing Session 1, the subjects will be administered 8 mg GSK356278 and placebo in a fasted state.
|
GSK356278
PLACEBO
|
Experimental: Cohort 2, Session 2
In Dosing Session 2, the subjects will be administered GSK356278 (8 mg and 16 mg) and placebo in a fasted state.
|
GSK356278
PLACEBO
|
Experimental: Cohort 2, Session 3
In Dosing Session 3, the subjects will be administered GSK356278 (16 mg and 30 mg) and placebo in a fasted state.
|
GSK356278
PLACEBO
|
Experimental: Cohort 2, Session 4
In Dosing Session 4, the subjects will be administered GSK356278 (30 mg and 50 mg) and placebo in a fasted state.
|
GSK356278
PLACEBO
|
Experimental: Cohort 2, Session 5
In Dosing Session 5, the subjects will be administered GSK356278 50 mg and placebo in a fasted state.
The subjects will undergo food assessment session in Session 5 incase they experience nausea.
In food assessment session, the subjects will receive a dose of GSK356278 after a standard breakfast.
|
GSK356278
PLACEBO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess safety and tolerability of single escalating oral doses of GSK356278 in healthy male volunteers
Time Frame: 72 hours
|
72 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To investigate the pharmacokinetics of single escalating doses of GSK356278 in healthy male volunteers
Time Frame: 72 hours
|
72 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 23, 2009
Primary Completion (Actual)
April 7, 2010
Study Completion (Actual)
April 7, 2010
Study Registration Dates
First Submitted
November 5, 2009
First Submitted That Met QC Criteria
December 10, 2009
First Posted (Estimate)
December 14, 2009
Study Record Updates
Last Update Posted (Actual)
July 27, 2017
Last Update Submitted That Met QC Criteria
July 25, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 113324
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Informed Consent Form
Information identifier: 113324Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 113324Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 113324Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 113324Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 113324Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 113324Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 113324Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder and Anxiety Disorders
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Senseye, Inc.RecruitingPTSD | Generalized Anxiety Disorder | Major Depressive DisorderUnited States
-
Nova Scotia Health AuthorityTerminatedGeneralized Anxiety Disorder | Major Depressive Disorder | Social Anxiety Disorder | Panic DisorderCanada
-
Babes-Bolyai UniversityCompletedAnxiety Disorders | Generalized Anxiety Disorder | Major Depressive Disorder | Social Anxiety Disorder | Panic Disorder | Persistent Depressive DisorderRomania
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedDepressive Disorder and Anxiety DisordersSweden
-
GlaxoSmithKlineCompletedDepressive Disorder and Anxiety DisordersUnited Kingdom
-
GlaxoSmithKlineCompletedDepressive Disorder and Anxiety DisordersUnited Kingdom
-
GlaxoSmithKlineCompletedDepressive Disorder and Anxiety DisordersUnited Kingdom
-
Instituto Nacional de Psiquiatría Dr. Ramón de...Harvard Medical School (HMS and HSDM); National Institute of Mental Health...RecruitingGeneralized Anxiety Disorder | Major Depressive DisorderColombia, Mexico
Clinical Trials on GSK356278
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted